Antares Pharma and Boston Scientific Look to Make Headway in Surging Medical Supplies Industry
The Paragon Report Provides Equity Research on Antares Pharma & Boston Scientific
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 03/22/12 -- Medical device and technology stocks have performed admirably in 2012. Year to date, the iShares Dow Jones U.S. Medical Devices Index Fund is up more than 15 percent. While investor sentiment appears positive at the moment, politicians and consumers are calling for greater oversight into the industry. Moreover, a medical device tax, which became law nearly 2 years ago as part of the Patient Protection & Affordable Care Act, is set to go into effect on January 1, 2013. The Paragon Report examines the outlook for companies in the Medical Equipment & Supplies industry and provides equity research on Antares Pharma Inc. (NYSE Amex: AIS) and Boston Scientific Corporation (NYSE: BSX). Access to the full company reports can be found at:
A recent Consumer Reports poll shows overwhelming public support for strong medical device safety oversight. The poll was released as House and Senate Committees have issued draft legislation to reauthorize the statute governing medical devices and at a time when the FDA's process for reviewing new implants has come under increased criticism. The House Energy and Commerce Health Subcommittee's draft bill would weaken device safety oversight and should be rejected by Congress, according to Consumers Union, the policy and advocacy arm of Consumer Reports.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Medical Equipment & Supplies industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Most medical devices don't require proof that they have been clinically tested and found to be safe and effective before they are cleared for distribution or sale by the Food and Drug Administration.
While much of the House calls for less oversight, a bipartisan foursome has crafted a Senate bill that would arm the FDA for stronger oversight of medical devices while also pushing it into action. The legislation would require the agency to issue a final Unique Device Identifier (UDI) rule by the end of 2012 and add medical devices to the FDA's Sentinel postmarket surveillance initiative.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2012 - 12:20 Uhr
Sprache: Deutsch
News-ID 127462
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Antares Pharma and Boston Scientific Look to Make Headway in Surging Medical Supplies Industry"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
